Comparison of outcomes with utilization of hyperthermic intraperitoneal chemotherapy with paclitaxel and cisplatin versus cisplatin alone at interval debulking surgery in women with epithelial ovarian cancer

M.P Horowitz,L Moulton Chambers,M Gruner,A.B Costales,M Morton,A.M Chichura,P.G Rose,C.M Michener,R Debernardo

doi:10.1016/j.ygyno.2020.06.113

Comparison of outcomes with utilization of hyperthermic intraperitoneal chemotherapy with paclitaxel and cisplatin versus cisplatin alone at interval debulking surgery in women with epithelial ovarian cancer

M.P Horowitz, L Moulton Chambers + Show 7 more

https://doi.org/10.1016/j.ygyno.2020.06.113

Copy DOI

Journal: Gynecologic oncology

Publication Date: Oct 1, 2020

Affiliation: Cleveland Clinic

#Epithelial Ovarian Cancer #Adverse Outcomes In Women + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Objective: The aim of this study was to investigate perioperative adverse outcomes in women with epithelial ovarian cancer (EOC) receiving interval debulking surgery (IDS) with hyperthermic intraperitoneal chemotherapy (HIPEC) with paclitaxel/cisplatin versus single-agent cisplatin.

Full Text